Technical Evaluation by CMAC

April 11, 2024|In News

In a significant stride towards advancing nanoparticle drug delivery manufacturing technology, LEON proudly announces a pioneering technical evaluation by CMAC, University of Strathclyde.

This joint effort brings together the expertise of Professor Yvonne Perrie and the team at CMAC with LEON’s science experts.

The aim of the studies was to test LEON’s proprietary state-of-the-art FR-JET formulation technology poised to reshape the landscape of nanoparticle manufacturing.




About LEON

leon-nanodrugs GmbH is a Munich-based pharmatech company specializing in the development of devices for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). LEON builds its innovative solutions based on its proprietary FR-JET technology. Its portfolio of devices, NANOlab® for process development, and NANOme® and NANOus® for GMP aseptic manufacturing, enable faster route to clinical batches and are suitable for both individualised scales and commercial production.

LEON’s platform is aimed at enabling pharma companies, small biotech, research institutes, as well as CDMOs, to take full advantage of the significant progress being made in advanced therapies.

For general information and enquiries please email